Balancing bleeding risk and clotting risk: How long should patients be on antiplatelet drugs following percutaneous coronary intervention?

By Dr. Brit Cooper-Jones A common challenge in the area of cardiovascular care is balancing bleeding risk versus clotting risk. Many people have heard of “antiplatelet drugs” (medications that reduce the risk of the blood forming clots) and may even be taking them themselves. Antiplatelet drugs play an important role in reducing the risk of heart attacks, strokes, and other clotting-related conditions. However, these same medications, by their very mechanism of reducing clot formation, also put patients at a higher risk of bleeding. As such, decisions around whom to prescribe antiplatelet drugs to – including what drug(s), and for how long – are not ones that are taken lightly. While antiplatelet drugs can be a lifesaving medication in many cases, we want to ensure that

from http://besthealthnews.com/2019/07/balancing-bleeding-risk-and-clotting-risk-how-long-should-patients-be-on-antiplatelet-drugs-following-percutaneous-coronary-intervention/

from
https://healthnews010.tumblr.com/post/186204317528

from https://johnher1.blogspot.com/2019/07/balancing-bleeding-risk-and-clotting.html

from
https://johnher10.tumblr.com/post/186204449132